Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1570 phase 1/2 study in advanced solid tumors
jRCT2031220527Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of ASP1570 in Nonhematologic neoplasms, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (7 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities, Adverse events and 3 more. Started May 2023; status: completed.
02
Drugs
ASP1570
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220527.